Who is sponsoring NCT02551848?

NCT02551848 is sponsored by Western University, Canada.

What condition does NCT02551848 study?

NCT02551848 studies Essential Tremor.

What drugs are being tested in NCT02551848?

Interventions: Botulinum toxin type A.

What is the status of NCT02551848?

NCT02551848 is currently UNKNOWN.

Last reviewed 2020-06-18 · How we verify

Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment

NCT02551848 Phase 2 UNKNOWN

The primary objective is to study the efficacy of botulinum toxin type A (Xeomin®) injected utilizing kinematically-based injection parameters for the treatment of upper extremity essential tremor (ET). Additional objectives are to study the benefit of kinematic assessment tools in determining injection parameters and to study the composition of tremor using kinematics.

Details

Lead sponsor	Western University, Canada
Phase	Phase 2
Status	UNKNOWN
Enrolment	25
Start date	2014-08
Completion	2021-12

Conditions

Essential Tremor

Interventions

Botulinum toxin type A

Primary outcomes

Kinematic tremor severity — 72 weeks
Change from pre to post-BoNT-A treatments in maximum angular tremor amplitude at the wrist in each treated arm. Angular tremor amplitude is one parameter reflecting the vectoral intensity of tremor segmented at each arm joint

Countries

Canada